Friday, August 8, 2014

Hornicek named first Mankin Endowed Scholar

CHAMPIONING COMPASSIONATE CARE: From left, Hornicek, Mankin and Rubash

Henry Mankin, MD, an honorary staff member and former chief of the MGH Department of Orthopædics, was recently recognized with a professorship named in his honor: the Henry J. Mankin, MD, Endowed Scholar in Orthopædics. Established through the generosity of grateful patients, former trainees, friends and the department, Mankin and the program’s first incumbent, Francis J. Hornicek, MD, PhD, chief of the Orthopædic Oncology Service, and co-director of the Center for Sarcoma and Connective Tissue Oncology, were celebrated June 26 at an event in the Paul S. Russell, MD Museum of Medical History and Innovation.

“In a career that spans more than 50 years, Dr. Mankin has touched and changed the lives of more than 19,000 patients with tumors and metabolic bone disease,” said Harry E. Rubash, MD, chief of the Department of Orthopædic Surgery. “He has shaped the professional lives of orthopædic surgeons around the globe, and he has advanced basic and clinical orthopædic research into clinical practice. His scholarly achievements have formed the foundation for much of standard orthopædic practice today.”

Mankin served as chief of Orthopædics from 1972 to 1996 and was founder and chief of the MGH Orthopædic Oncology Service from 1972 to 2000. He is well-known for pioneering innovative and life-saving treatments for individuals with musculoskeletal tumors.

“I am filled with gratitude,” said Mankin. “I cannot think of a more fitting first incumbent than my successor Dr. Hornicek, who has inspired me by tirelessly expanding the limits of what we know, constantly creating new and better ways of treating patients and continually focusing on improving patient care and support.”

Like Mankin, Hornicek exemplifies a commitment to research in orthopædic oncology and an unwavering dedication to outstanding and compassionate care for his patients, said Rubash. He is a leading authority in the field of musculoskeletal oncology and is recognized as an international expert in the management of sarcomas – some of the rarest types of tumors. Hornicek’s role in the discovery of novel therapeutics for sarcomas and his research into the development of new chemotherapeutic drugs have led to promising clinical trials and patent applications.

“I am honored by this appointment bearing Dr. Mankin’s name,” said Hornicek. “I have had the privilege of following in his footsteps. I hope to build on his successes and continue his legacy of exceptional care.”

Read more articles from the 08/08/14 Hotline issue.


Back to Top